引文
[1]Satirapoj B,Adler SG.Prevalence and Management of Diabetic Nephropathy in Western Countries[J].Kidney Dis(Basel),2015,1(1):61-70.doi:10.1159/000382028.
[2]Wang ZS,Xiong F,Xie XH,et al.Astragaloside IVattenuates proteinuria in streptozotocin-induced diabetic nephropathy via the inhibition of endoplasmic reticulum stress[J].BMC Nephrol,2015,16:44.doi:10.1186/s12882-015-0031-7.
[3]Guclu A,Erdur FM,Turkmen K.The Emerging Role of Sirtuin 1 in Cellular Metabolism,Diabetes Mellitus,Diabetic Kidney Disease and Hypertension[J].Exp Clin Endocrinol Diabetes,2016,124(3):131-139.doi:10.1055/s-0035-1565067.
[4]Teng B,Duong M,Tossidou I,et al.Role of protein kinase C in podocytes and development of glomerular damage in diabetic nephropathy[J].Front Endocrinol(Lausanne),2014,5:179.doi:10.3389/fendo.2014.00179.
[5]Xiao B,Liu B,Song Y,et al.Local cytotoxic T-lymphocyte-associated antigen-4 immunoglobulin inhibition of rejection response is dependent on indoleamine 2,3-dioxygenase activities in the allograft[J].Transplant Proc,2014,46(10):3637-3640.doi:10.1016/j.transproceed.2014.06.072.
[6]Bo rje Haraldsson.A new era of podocyte targeted therapy for proteinuric kidney disease[J].N Engl J Med,2013,369(25):2453-2454.doi:10.1056/NEJMe1312835.
[7]Ma R,Liu L,Liu X,et al.Triptolide markedly attenuates albuminuria and podocyte injury in an animal model of diabetic nephropathy[J].Exp Ther Med,2013,6(3):649-656.doi:10.3892/etm.2013.1226.
[8]Ricci P,Maggini E,Mancuso E,et al.Clinical application of breast1793elastography:state of the art[J].Eur J Radiol,2014,83(3):429-437.doi:10.1016/j.ejrad.2013.05.007.
[9]Ilyas Z,Chaiban JT,Krikorian A.Novel insights into the pathophysiology and clinical aspects of diabetic nephropathy[J].Rev Endocr Metab Disord,2017,18(1):21-28.doi:10.1007/s11154-017-9422-3.
[10]Liu Y,Tang SC.Recent Progress in Stem Cell Therapy for Diabetic Nephropathy[J].Kidney Dis,2016,2(1):20-27.doi:10.1159/000441913.
[11]Kim SS,Kim JH,Kim IJ.Current Challenges in Diabetic Nephropathy:Early Diagnosis and Ways to Improve Outcomes[J].Endocrinology and Metabolism,2016,31(2):245-253.doi:10.3803/EnM.2016.31.2.245.
[12]Toth-Manikowski S,Atta MG.Diabetic Kidney Disease:Pathophysiology and Therapeutic Targets[J].J Diabetes Res,2015,2015:697010.doi:10.1155/2015/697010.
[13]Yu CC,Fornoni A,Weins A,et al.Abatacept in B7-1-Positive Proteinuric Kidney Disease[J].N Engl J Med,2013,369(25):2416-2423.doi:10.1056/NEJMoa1304572.
[14]Kirtee Raparia,Irtaza Usman,Yashpal S,et al.Renal Morphologic Lesions Reminiscent of Diabetic Nephropathy[J].Archives of Pathology&Laboratory Medicine,2013,137(3):351-359.doi:10.5858/arpa.2012-0243-RA.
[15]Freitas SC,Harthmann A(d,Rodrigues B,et al.Effect of aerobic exercise training on regional blood flow and vascular resistance in diabetic rats[J].DiabetolMetab Syndr,2015,7:115.doi:10.1186/s13098-015-0109-1.
[16]Brabrand K,de Lange C,Emblem KE,et al.Contrast-enhanced ultrasound identifies reduced overall and regional renal perfusion during global hypoxia in piglets[J].Invest Radiol,2014.49(8):540-546.doi:10.1097/RLI.0000000000000053.
[17]Verzola D,Cappuccino L,D'Amato E,et al.Enhanced glomerular Toll-like receptor 4 expression and signaling in patients with type 2 diabetic nephropathy and microalbuminuria[J].Kidney Int,2014,86(6):1229-1243.doi:10.1038/ki.2014.116.
[18]Bentata Y,Latrech H,Abouqal R.Does body mass index influence the decline of glomerular filtration rate in diabetic type 2patients with diabetic nephropathy in a developing country[J]?Ren Fail,2014,36(6):838-846.doi:10.3109/0886022X.2014.899472.
[19]Dai H,Liu Q,Liu B.Research Progress on Mechanism of Podocyte Depletion in Diabetic Nephropathy[J].J Diabetes Res,2017,2017:2615286.doi:10.1155/2017/2615286.
[20]Nair AR,Masson GS,Ebenezer PJ,et al.Role of TLR4 in lipopolysaccharide-induced acute kidney injury:protection by blueberry[J].Free Radic BiolMed,2014,71:16-25.doi:10.1016/j.freeradbiomed.2014.03.012.
[21]Zhou Y,Zhu N,Wang X,et al.The role of the toll-like receptor TLR4 in hepatitis B virus-associated glomerulonephritis[J].Arch Virol,2013,158(2):425-433.doi:10.1007/s00705-012-1508-3.
[22]Ma J,Chadban SJ,Zhao CY,et al.TLR4 activation promotes podocyte injury and interstitial fibrosis in diabetic nephropathy.PLoS One,2014,9(5):e97985.doi:10.1371/journal.pone.0097985.